Drug intelligence / Profile preview

laperosudil

Development stage: Unknown
Lead developer: Shenzhen Jianyuan Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Laperosudil (LH025) is an orally administered small molecule Rho-kinase (ROCK) inhibitor developed by Shenzhen Jianyuan Pharmaceutical Technology. It is primarily being investigated for the treatment of mild to moderate active ulcerative colitis. By inhibiting ROCK1 and ROCK2, laperosudil aims to modulate the inflammatory response, specifically by influencing the balance between pro-inflammatory Th17 cells and anti-inflammatory Treg cells, and by reducing the production of cytokines such as TNF-α and IL-17. The drug is formulated as laperosudil acetate and has been evaluated in Phase I clinical trials to assess its safety, pharmacokinetics, and preliminary efficacy in adult patients.

Other names: laperosudil acetate

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on laperosudil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on laperosudil.

Explore the full profile